Navigation Links
Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Date:4/14/2009

LA JOLLA, Calif., April 14 /PRNewswire/ -- Zenobia Therapeutics, Inc., the leader in fragment-based lead discovery for diseases of the central nervous system, announced successful completion of the first phase of its services agreement with Syntonix Pharmaceuticals, a wholly-owned subsidiary of Biogen Idec (Nasdaq: BIIB). As part of the agreement, Syntonix gains access to Zenobia's technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia completed three unique protein structures during the first five months of the agreement. The agreement includes research funding and milestone payments.

"Syntonix challenged us with a difficult program, and through close collaboration between our scientists, we are pleased to deliver results," said Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia.

The program required dedicated expertise in protein crystallization including specialized techniques and multiple rounds of optimization.

"It was a challenging target to crystallize, with more than 800 conditions being screened followed by careful optimization of multiple parameters, which was a key for successful structure determination," said Vandana Sridhar, head of Zenobia's crystallization group.

Zenobia has rapid access to high-energy synchrotron sources for data collection through an agreement with Shamrock Biostructures, located near the Advanced Photon Source (APS) in Chicago, IL.

"Synchrotron radiation was required for this program, and we are fortunate to have routine access to the only third-generation synchrotron in the U.S. through our agreement with Shamrock," said Dr. Nienaber.

"Having access to these new experimental crystal structures will allow us to more efficiently design and develop our internal drug
'/>"/>

SOURCE Zenobia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
4. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
5. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
6. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
7. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
8. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
9. Arno Therapeutics Reports 2008 Year-End Financial Results
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Steep Hill, the industry leader in ... intends to open a full service medical cannabis quality ... , bringing advanced scientific tools and methodology to the ... Hill is currently the only laboratory licensed by the ... contaminant testing in order to meet the recently adopted ...
(Date:2/26/2015)... 2015  23andMe, the leading personal genetics company, today ... Privacy Officer and Corporate Counsel. Black brings a strong ... well as health care regulations. As a member of ... for reviewing, updating and enhancing the company,s privacy and ... She joined the company January 5, 2015 and reports ...
(Date:2/26/2015)... PARK, Calif. , Feb. 26, 2015 ... released the latest version of the Governance Portal ... accomplish governance, risk and compliance (GRC) tasks across multiple ... also been updated to help customers better align their ... of the Treadway Commission ) requirements. In response to ...
(Date:2/26/2015)... 2015  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), ... and hair rejuvenation, has announced that it has ... for investor relations and strategic communications. ... and diversification strategies – and we need to ... stated Ali Kharazmi CEO of NuGene when announcing ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 223andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... , ... , , , ... samples of low cell numbers , , , ... cells have, for example,limited availability, quantity,and lifespan. Using the Agilent,2100 bioanalyzer ...
... , , , ... , , , , ... Agilent 2100 bioanalyzer can,be used to analyze apoptotic cell samples. Performance ... compared to,those obtained with a conventional flow cytometer. Histogram quality,of the ...
... , , , , ... The In Situ Cell Death Detection Kit has been designed as a precise, fast, and simple, ... the single-cell level in tissues. It is based on the so-called TUNEL, ... , , , , ...
Cached Biology Technology:Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 2Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 2Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 4Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 5Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 6Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 7Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 8Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 9In Situ Cell Death Detection Kit 2
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... the Exploitation of Meteorological Satellites, agreed today that ... the last two Meteosat Second Generation (MSG) satellites, ... will provide control services during the critical launch ... the satellite from its initial position after separation ...
... 6 Foregoing food for a day each month ... the Church of Jesus Christ of Latter-Day Saints (LDS ... than other Americans, researchers reported at the American Heart ... receive a heart-protective benefit, and this appeared to also ...
... if the babies have a genetic variant that enhances their ... today in Proceedings of the National Academy of Sciences. ... in the control of fatty acid pathways, that may help ... promote the brain development that is associated with a higher ...
Cached Biology News:ESA to provide essential launch control services to EUMETSAT 2ESA to provide essential launch control services to EUMETSAT 3People who skip meals: are they better off? 2People who skip meals: are they better off? 3Breastfeeding boost IQ in infants with 'helpful' genetic variant 2